315 related articles for article (PubMed ID: 20647928)
21. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy.
Bouzourene H; Bosman FT; Seelentag W; Matter M; Coucke P
Cancer; 2002 Feb; 94(4):1121-30. PubMed ID: 11920483
[TBL] [Abstract][Full Text] [Related]
22. cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted.
Guillem JG; Díaz-González JA; Minsky BD; Valentini V; Jeong SY; Rodriguez-Bigas MA; Coco C; Leon R; Hernandez-Lizoain JL; Aristu JJ; Riedel ER; Nitti D; Wong WD; Pucciarelli S
J Clin Oncol; 2008 Jan; 26(3):368-73. PubMed ID: 18202411
[TBL] [Abstract][Full Text] [Related]
23. Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients.
Bonnen M; Crane C; Vauthey JN; Skibber J; Delclos ME; Rodriguez-Bigas M; Hoff PM; Lin E; Eng C; Wong A; Janjan NA; Feig BW
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1098-105. PubMed ID: 15519780
[TBL] [Abstract][Full Text] [Related]
24. [Tumor downstaging through preoperative chemoradiotherapy in locally advanced rectal cancer].
Liang H; Schlag PM
Zhonghua Zhong Liu Za Zhi; 2002 Jan; 24(1):77-9. PubMed ID: 11977647
[TBL] [Abstract][Full Text] [Related]
25. What factors affect lymph node yield in surgery for rectal cancer?
Thorn CC; Woodcock NP; Scott N; Verbeke C; Scott SB; Ambrose NS
Colorectal Dis; 2004 Sep; 6(5):356-61. PubMed ID: 15335370
[TBL] [Abstract][Full Text] [Related]
26. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
[TBL] [Abstract][Full Text] [Related]
27. Location of rectal cancer within the circumference of the rectum does not influence lymph node status.
Ulrich A; Himmer K; Koch M; Kienle P; Büchler MW; Weitz J
Ann Surg Oncol; 2007 Aug; 14(8):2257-62. PubMed ID: 17520316
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors for disease-free survival in patients with T3-4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation.
Díaz-González JA; Calvo FA; Cortés J; García-Sabrido JL; Gómez-Espí M; Del Valle E; Muñoz-Jiménez F; Alvarez E
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1122-8. PubMed ID: 16406393
[TBL] [Abstract][Full Text] [Related]
29. Indication and benefit of pelvic sidewall dissection for rectal cancer.
Sugihara K; Kobayashi H; Kato T; Mori T; Mochizuki H; Kameoka S; Shirouzu K; Muto T
Dis Colon Rectum; 2006 Nov; 49(11):1663-72. PubMed ID: 17041749
[TBL] [Abstract][Full Text] [Related]
30. Analysis of early postoperative morbidity among patients with rectal cancer treated with and without neoadjuvant chemoradiotherapy.
Valenti V; Hernandez-Lizoain JL; Baixauli J; Pastor C; Aristu J; Diaz-Gonzalez J; Beunza JJ; Alvarez-Cienfuegos JA
Ann Surg Oncol; 2007 May; 14(5):1744-51. PubMed ID: 17334851
[TBL] [Abstract][Full Text] [Related]
31. Selective lateral pelvic lymph node dissection in patients with advanced low rectal cancer treated with preoperative chemoradiotherapy based on pretreatment imaging.
Akiyoshi T; Ueno M; Matsueda K; Konishi T; Fujimoto Y; Nagayama S; Fukunaga Y; Unno T; Kano A; Kuroyanagi H; Oya M; Yamaguchi T; Watanabe T; Muto T
Ann Surg Oncol; 2014 Jan; 21(1):189-96. PubMed ID: 23963871
[TBL] [Abstract][Full Text] [Related]
32. Absence of lymph nodes in the resected specimen after radical surgery for distal rectal cancer and neoadjuvant chemoradiation therapy: what does it mean?
Habr-Gama A; Perez RO; Proscurshim I; Rawet V; Pereira DD; Sousa AH; Kiss D; Cecconello I
Dis Colon Rectum; 2008 Mar; 51(3):277-83. PubMed ID: 18183463
[TBL] [Abstract][Full Text] [Related]
33. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
34. Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers.
Lim SB; Choi HS; Jeong SY; Kim DY; Jung KH; Hong YS; Chang HJ; Park JG
Ann Surg; 2008 Aug; 248(2):243-51. PubMed ID: 18650634
[TBL] [Abstract][Full Text] [Related]
35. Pathological changes of advanced lower-rectal cancer by preoperative radiotherapy.
Kinoshita H; Watanabe T; Yanagisawa A; Nagawa H; Kato Y; Muto T
Hepatogastroenterology; 2004; 51(59):1362-6. PubMed ID: 15362753
[TBL] [Abstract][Full Text] [Related]
36. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
37. Metastatic lymph node ratio in stage III rectal carcinoma is a valuable prognostic factor even with less than 12 lymph nodes retrieved: a prospective study.
Madbouly KM; Abbas KS; Hussein AM
Am J Surg; 2014 Jun; 207(6):824-31. PubMed ID: 24112666
[TBL] [Abstract][Full Text] [Related]
38. Comparative outcome between chemoradiotherapy and lateral pelvic lymph node dissection following total mesorectal excision in rectal cancer.
Kim JC; Takahashi K; Yu CS; Kim HC; Kim TW; Ryu MH; Kim JH; Mori T
Ann Surg; 2007 Nov; 246(5):754-62. PubMed ID: 17968166
[TBL] [Abstract][Full Text] [Related]
39. Preoperative chemoradiotherapy (CRT) followed by laparoscopic surgery for rectal cancer: predictors of the tumor response and the long-term oncologic outcomes.
Lee JH; Kim SH; Kim JG; Cho HM; Shim BY
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):431-8. PubMed ID: 20732756
[TBL] [Abstract][Full Text] [Related]
40. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
